Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642512 · ClinicalTrials.gov registry record · Phase 3
Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 64
- Enrollment target
NCT00642512 is a Phase 3 study that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 64 participants.
The verdict
NCT00642512, a Phase 3 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 64 participants
- Enrollment target
Study Summary
The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring the incidence of total response of nausea and vomiting and/or retching following administration of moderate-to-high emetogenic chemotherapeutic agents.
Interventions
- DRUG placebo
- DRUG ondansetron
- DRUG dronabinol
- DRUG dronabinol/ondansetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2003-07 |
| Est. Completion | 2004-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00642512
The ClinicalTrials.gov registry entry for NCT00642512 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00642512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00642512 about?
NCT00642512 is a clinical study titled "Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting". The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring the incidence of total response of nausea and vomiting and/or retching ...
What is the current status of trial NCT00642512?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 64 participants. The study started on 2003-07. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00642512?
The interventions under investigation include: placebo (DRUG), ondansetron (DRUG), dronabinol (DRUG), dronabinol/ondansetron (DRUG).
Who is sponsoring clinical trial NCT00642512?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.